Nitronal

prophylaxis of Angina pectoris, Congestive Heart Failure, Chest Pain + 10 more

Treatment

18 Active Studies for Nitronal

What is Nitronal

Nitroglycerin

The Generic name of this drug

Treatment Summary

Nitroglycerin is a medication used to reduce chest pain and lower blood pressure. It is available in many different forms, such as a spray, tablets, injections, and a skin patch. Nitroglycerin is also used in an ointment form to treat pain from anal fissures, and was approved by the FDA in 1955.

Nitroglycerin

is the brand name

Nitronal Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nitroglycerin

Nitroglycerin

1981

182

Effectiveness

How Nitronal Affects Patients

Nitroglycerin helps to relax the walls of blood vessels, increasing blood flow to the heart and decreasing the stress on the heart muscle. It also helps reduce spasm in the coronary arteries, which lowers overall blood pressure. Taking it for long periods of time can cause the body to become less responsive to nitroglycerin, and it can also cause oxidative damage, dysfunction of the endothelium, and an increase in sensitivity to substances that constrict blood vessels.

How Nitronal works in the body

Nitroglycerin helps relax blood vessels and increase blood flow by converting to nitric oxide in the body. Nitric oxide then activates an enzyme called guanylate cyclase, which creates a molecule called cyclic guanosine monophosphate (cGMP). cGMP causes proteins in blood vessels and other tissues to relax, allowing more blood to flow and lowering blood pressure. Nitric oxide may also interact with natriuretic peptide receptors, though this has not been proven yet.

When to interrupt dosage

The advised measure of Nitronal is based on the diagnosed ailment, including Coronary Artery Spasm, induction of Uterine ease and Anal Fissure. The amount of dosage shifts, depending on the technique of delivery (e.g. Tablet or Tablet - Oral) declared in the chart beneath.

Condition

Dosage

Administration

Chest Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Coronary Disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Anal Fissure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

induction of Intraoperative Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

insufficient response to beta-blockers

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

nitroglycerin

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Angina Pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Congestive Heart Failure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypertensive disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

prophylaxis of Angina pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Myocardial Infarction

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Warnings

Nitronal has eleven contraindications and should not be administered alongside the conditions specified in the table below.

Nitronal Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nitroglycerin may interact with Pulse Frequency

Cardiac Tamponade

Do Not Combine

Pulse Frequency

Do Not Combine

Hypovolemic Shock

Do Not Combine

Anemia

Do Not Combine

Pick Disease of Heart

Do Not Combine

Pulse Frequency

Do Not Combine

Acute Circulatory Failure

Do Not Combine

Intracranial Hypertension

Do Not Combine

Cardiomyopathy, Restrictive

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Nitronal.

Common Nitronal Drug Interactions

Drug Name

Risk Level

Description

Amediplase

Major

The therapeutic efficacy of Amediplase can be decreased when used in combination with Nitroglycerin.

Amifostine

Major

Nitroglycerin may increase the hypotensive activities of Amifostine.

Desmoteplase

Major

The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Nitroglycerin.

Reteplase

Major

The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.

Riociguat

Major

Nitroglycerin may increase the hypotensive activities of Riociguat.

Nitronal Toxicity & Overdose Risk

The toxic dose of nitroglycerin in rats is 105mg/kg taken orally, and 23.2mg/kg taken intravenously. Overdosing on nitroglycerin can cause low blood pressure, headache, dizziness, palpitations, blurred vision, flushing and cold skin, nausea and vomiting (sometimes with blood in the vomit), fainting (especially when standing up), blue skin due to lack of oxygen, confusion, paralysis and seizures, and possibly death due to loss of circulation. Methemoglobinemia, a condition where not enough oxygen is delivered to the body's cells, can also occur

Nitronal Novel Uses: Which Conditions Have a Clinical Trial Featuring Nitronal?

38 active clinical trials are currently investigating the use of Nitronal to prevent Gastroesophageal variceal hemorrhage, reduce Hypotension and treat Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Coronary Disease

1 Actively Recruiting

Not Applicable

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pain

0 Actively Recruiting

prophylaxis of Angina pectoris

0 Actively Recruiting

Hypertensive disease

0 Actively Recruiting

induction of Intraoperative Hypotension

0 Actively Recruiting

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Anal Fissure

1 Actively Recruiting

Phase 1

Hypotension

0 Actively Recruiting

insufficient response to beta-blockers

0 Actively Recruiting

Angina Pectoris

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

nitroglycerin

0 Actively Recruiting

Patient Q&A Section about nitronal

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Nitronal used for?

"Nitroglycerin injection is a medication used to treat high blood pressure during surgery or to control congestive heart failure in patients who have had a heart attack. It may also be used to produce low blood pressure during surgery."

Answered by AI

What is the action of injection nitroglycerin?

"Nitroglycerin is a kind of medicine called a nitrate. Nitrates work by relaxing blood vessels and increasing the supply of blood and oxygen to the heart, while reducing the heart's workload. Nitroglycerin should only be given by or under the direct supervision of a doctor."

Answered by AI

What is Tridil infusion?

"It is used to control high blood pressure, congestive heart failure, lung congestion and chest pain. It decreases the workload on the heart by dilating blood vessels."

Answered by AI

How do I start NTG infusion?

"The initial dose of this medication is a continuous IV infusion of 0.25 to 0.5 mcg/kg/minute. The dose should be increased by 1 mcg/kg/minute IV every 15 to 20 minutes as tolerated. The usual dosage range is 1 to 5 mcg/kg/minute, but the maximum dosage is 10 mcg/kg/minute. In some cases, rates up to 20 mcg/kg/minute have been used."

Answered by AI

Clinical Trials for Nitronal

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Have you considered Nitronal clinical trials?

We made a collection of clinical trials featuring Nitronal, we think they might fit your search criteria.
Go to Trials
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA

The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.

Waitlist Available
Has No Placebo

Ronald Reagan UCLA Medical Center

Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Have you considered Nitronal clinical trials?

We made a collection of clinical trials featuring Nitronal, we think they might fit your search criteria.
Go to Trials
Image of Saint Luke's Hospital of Kansas City in Kansas City, United States.

Remote Patient Monitoring for Heart Failure

18 - 80
All Sexes
Kansas City, KS

Previous research has investigated the use of remote patient monitoring in various clinical contexts, however there has not been a clinical trial examining use of the VitalCare platform for ambulatory management of heart failure. This trial will serve as a pilot study examining the feasibility of use of the VitalCare platform for ambulatory heart failure management and examine the effect of remote patient monitoring on patient engagement. To the investigators' knowledge, this will be the first study examining the effect of remote patient monitoring with the VitalCare platform on heart failure clinical outcomes, such as hospitalization for heart failure exacerbations and emergency room visits for heart failure.

Waitlist Available
Has No Placebo

Saint Luke's Hospital of Kansas City (+3 Sites)

Image of Columbia University Medical Center/ NewYork Presbyterian Hospital in New York, United States.

CTO PCI for Chronic Total Occlusions

18+
All Sexes
New York, NY

Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success rates at subsequent attempts. It has never been investigated whether a planned investment procedure, with an intention that both the initial and staged completion PCI are of shorter duration, could improve safety and efficacy. The investigators hypothesize that 1. A planned investment procedure in the treatment of CTOs will be associated with improved patient safety 2. A planned investment procedure will be associated with improved cumulative procedure success rates 3. A planned two stage procedure will be associated with improved patient experience

Waitlist Available
Has No Placebo

Columbia University Medical Center/ NewYork Presbyterian Hospital

Margaret B Mcentegart, PhD

Have you considered Nitronal clinical trials?

We made a collection of clinical trials featuring Nitronal, we think they might fit your search criteria.
Go to Trials